LCM
ICPT

Laurion Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Laurion Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-239,533
Closed -$24.1M – 1394
2018
Q4 		$24.1M Buy
+239,533
New +$24.8M 0.43% 42

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Laurion Capital Management's ICPT Position: Q1 2019 in Review

Laurion Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2019, closing a stake of 239,533 shares — an estimated $24.1M sold.

Laurion Capital Management first reported a position in ICPT in Q4 2018 and held it in 1 quarter. The position peaked at $24.1M in Q4 2018. 202 funds tracked by Wall St. Rank hold ICPT as of Q1 2019.

  • Laurion Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Laurion Capital Management sold 239,533 Intercept Pharmaceuticals, Inc. shares in Q1 2019, an estimated $24.1M.
  • Laurion Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Laurion Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $24.1M in Q4 2018.
  • 202 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2019.

Based on Laurion Capital Management's 13F filing for Q1 2019, filed 8 May 2019.